INTRODUCTION {#s1}
============

Considerable progress had been made in developing targeted therapies for genomic subtypes in cancer, but patient selection for these therapies can be challenging. Radiogenomics (sometimes imaging genomics) is a new, rapidly evolving field of research aimed at developing tools for non-invasive genotyping by identifying imaging biomarkers for genomic subtypes \[[@R1]--[@R3]\]. Radiogenomic analysis refers to the integration of radiophenotypes and genomic data in order to find radiogenomic associations (Figure [1](#F1){ref-type="fig"}). Radiogenomic analysis can be performed using qualitative- or quantitative (computer-extracted, radiomics) imaging features, which can be used as individual biomarkers or can be incorporated in multiparametric prediction models.

![Illustration of the research methods of radiogenomics](oncotarget-09-20134-g001){#F1}

Radiogenomics yields considerable advantages for genotyping. Firstly, tumor genetic heterogeneity can be captured using radiogenomics. Biopsy-based genotyping in the clinical setting is generally confined to a single sample, although multiregional genotyping has been performed effectively to capture tumor heterogeneity \[[@R4]--[@R6]\]. Radiogenomic biomarkers have shown a great potential for capturing tumor heterogeneity non-invasively \[[@R7], [@R8]\]. Secondly, a non-invasive method can be performed repeatedly, and is therefore eminently suitable for treatment follow-up. In addition, radiogenomic markers are important for tumors for which biopsy is unavailable (e.g. glioma, retinoblastoma) \[[@R9]\]. Finally, radiogenomics is fast and cost-effective, generally using routine clinical imaging. Several non-systematic reviews were published on radiogenomics \[[@R2], [@R3], [@R10]--[@R19]\]. The main purpose of this systematic review was to provide a comprehensive oncology-wide database of radiogenomic associations, and to review their clinical usefulness. A secondary objective was to assess radiogenomics on a pathway-level instead of a gene-level; to perform oncology-wide gene pathway analysis in order to identify relations between imaging and oncopathways.

RESULTS {#s2}
=======

Database of imaging-genomics associations {#s2_1}
-----------------------------------------

We included 187 articles published between July 2004 and February 2017. A PRISMA flow diagram for the inclusion process is available in the [Supplementary Table 1](#SD2){ref-type="supplementary-material"}. Figure [2](#F2){ref-type="fig"} illustrates the exponential growth of publications on a year-over-year basis. The major groups reflected diffuse glioma (*n* = 79, 42%), non-small cell lung cancer (NSCLC) (*n* = 51, 27%), and breast cancer (*n* = 18, 10%). Often, studies used multiple modalities; 105 studies used MRI (56%), 80 CT (43%), 44 FDG-PET (24%), and 5 mammography (3%). In 59/187(32%) articles biological clarifications for imaging-genomics relations were identified. The 2440 identified radiogenomic associations in the database are presented as a pivot table, which provides an easy graphical interface to perform data queries using Microsoft Excel (2010/2013) ([Supplementary Table 2](#SD3){ref-type="supplementary-material"}). Study characteristics and quality assessment are available in the [Supplementary Table 3](#SD4){ref-type="supplementary-material"}. The results section focuses on repeatedly identified imaging-genomics associations with possible clinical application.

![The number of included articles per type of neoplasm, by year of publication](oncotarget-09-20134-g002){#F2}

Glioma: *IDH*-mutation status and 1p/19q codeletion {#s2_2}
---------------------------------------------------

The 2016 World Health Organisation (WHO) Central Nervous System (CNS) tumor classification uses a combined phenotypic (histology) and genotypic classification for diffuse glioma (diffuse astrocytic and oligondendroglial tumors grade II-IV) \[[@R20]\]. The major genetic traits are *IDH* mutation and 1p/19q codeletion, both associated with a more favourable prognosis \[[@R21]--[@R26]\]. Table [1](#T1){ref-type="table"} summarizes radiogenomics for *IDH*-status in glioblastoma (GBM, grade IV glioma), while Table [2](#T2){ref-type="table"} and [Supplementary Table 4](#SD5){ref-type="supplementary-material"} show radiogenomics results for *IDH*-status and 1p/19q codeletion in grade II-III glioma. On MRI, *IDH*-mutated cases were characterised by increased perfusion parameters in both glioblastoma (higher tumor blood flow) \[[@R27]\] and grade II glioma (higher relative cerebral blood volume) \[[@R28]\]. Additionally, detection of 2-hydroxyglutarate (2-HG) with MR-spectroscopy (MRS) was a strong predictor of *IDH*-mutations in glioblastoma (grade IV) \[[@R29]\], grade II-III glioma \[[@R30]\] and grade II-III-IV glioma \[[@R31]\]. Furthermore, four studies applied multiparametric models predicting *IDH*-status based on qualitative and quantitative features ([Supplementary Table 5](#SD6){ref-type="supplementary-material"}) \[[@R32]--[@R35]\]. 1p/19q codeletion, a pathognomonic trait that defines a distinct glioma entity (oligodendroglioma), was associated with ill-defined tumor borders \[[@R36]--[@R39]\] and tumor heterogeneity \[[@R36]--[@R39]\] on MRI of grade II-III glioma. Results of one study revealed combined perfusion and MRS metabolite ratios can discriminate tumors with 1p/19q loss of heterozygosity with an accuracy of 72% \[[@R40]\]. MGMT-methylations status is relevant for glioblastoma, as it could aid patient selection for adjuvant temozolamide chemotherapy \[[@R41]--[@R43]\]. [Supplementary Table 6](#SD7){ref-type="supplementary-material"} summarizes findings of studies assessing *MGMT*-methylation status \[[@R27], [@R32], [@R44]--[@R52]\] in glioblastoma. *MGMT*-methylated tumors showed higher apparent diffusion coefficient (ADC) values on diffusion weighted-MRI (DW-MRI) in four out of five studies \[[@R27], [@R44]--[@R47]\]. [Supplementary Table 7](#SD8){ref-type="supplementary-material"} summarizes the findings of studies correlating MR features with *EGFR*-status in diffuse glioma. MR perfusion parameters correlated with *EGFR*-amplification \[[@R53]\], and *EGFR*-mutation status in glioblastoma \[[@R54], [@R55]\] and with *EGFR*-expression in grade II-II oligodendroglioma \[[@R56]\] and grade III-IV glioma \[[@R57]\].

###### Overview of radiogenomics for predicting IDH mutation status in glioblastoma (grade IV), *p*-values for associations

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                       Necrosis      Enhancement                  Diffusion                            Perfusion                                           MRS                                                  Other                                                                                            
  ---------------------- ------------------ ---------- ---------------- -------------- ------------- ---------------------------- ------------------------------------ --------------------------------------------------- ---------------------------------------------------- --------------------------------------------------------------- -------------------------------- -----------------------
  *IDH*-mutations        *Glioma grade*     *Author*   *Year of pub.*   *N*            MR Necrosis   MR CE Contrast enhancement   MR CE Contrast enhancement pattern   MR ADC apparent diffusion coefficient (mean; min)   MR TBF tumour blood flow (mean absolute; relative)   MRS (magnetic resonance spectroscopy) 2-HG metabolite imaging   MR Edema (brain; peritumoural)   MR Nonenhanced tumour

  Grade IV               Choi \[[@R161]\]   **2012**   29                                                                                                                                                                  **\<0.001**                                                                                                                                           

  Gutman \[[@R192]\]     **2013**           75         0.19             0.08                                                                                                                                               0.6                                                  0.23                                                                                             

  Wang \[[@R200]\]       **2015**           280                         **\<0.001**\   0.621                                                                                                                               0.395                                                                                                                                                 
                                                                        **0.003**                                                                                                                                                                                                                                                                                                

  Yamashita \[[@R27]\]   **2016**           55         **\<0.05**                                    \>0.05\                      **\<0.001**\                                                                                                                                                                                                                                   
                                                                                                     \>0.05                       **\<0.001**                                                                                                                                                                                                                                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Overview of radiogenomics for predicting IDH mutation status in glioma grade II-III, *p*-values for associations

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                           Volume                 Margin                                     Location                   Calcification           Heterogeneity                 Enhancement                             Perfusion                                          MRS                                                                 PET                                                     
  ------------------------- ---------------------- ---------- ---------------- ----------- ---------------------- ------------------------------------------ -------------------------- ----------------------- ----------------------------- --------------------------------------- -------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------- -----------------------
  *IDH*-mutations           *Glioma grade*         *Author*   *Year of pub.*   *N*         **MR Tumour volume**   **MR Tumour margin well poorly defined**   **MR Location features**   **CT Calcifications**   **MR Heterogeneity**          **MR CE contrast enhancement tumour**   **MR CBV cerebral blood volume 90th percentile**   **MRS (magnetic resonance spectroscopy) 2-HG metabolite imaging**   MRS Magnetic resonance spectroscopy other metabolites   PET FDG SUV max ratio

  Grade II                  Yu \[[@R201]\]         **2017**   92                                                  **0.007**                                                                                                                                                                                                                                                                                                                                          

  Kickingreder \[[@R28]\]   **2015**               73                                                                                                                                                           AUC 0.922 OR 031 **p 0.01**                                                                                                                                                                                                                          

  Wang \[[@R202]\]          **2015**               146                                     **\<0.05**                                                                                                                                                                                                                                                                                                                                                                

  Metellus \[[@R203]\]      **2010**               47         0.047            **0.007**   **0.004**                                                         0.82                       0.99                                                                                                                                                                                                                                                                         

  Grade II, III             Metellus \[[@R204]\]   **2011**   33                                                                                                                                                                                                                                                                                                                                             0.775                                                   

  Pope \[[@R30]\]           **2012**               24                                                                                                                                                                                         **0.003**                                                                                                                                                                                                              

  Saito \[[@R205]\]         **2016**               250                                                            **0.0004**                                                                                                                                                                                                                                                                                                                                         

  Grade II, III, IV         Nakae \[[@R206]\]      **2016**   167                                                                                                                                                                                                                                                                        **\<0.001**--0.49                                                                                                           

  Kalinina \[[@R31]\]       **2012**               75                                                                                                                                                                                         Sens 0.960\                                                                                                                                                                                                            
                                                                                                                                                                                                                                              Spec 0.952\                                                                                                                                                                                                            
                                                                                                                                                                                                                                              ***P* \< 0.001**                                                                                                                                                                                                       
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Multiparametric modelling for radiogenomics in diffuse glioma {#s2_3}
-------------------------------------------------------------

[Supplementary Table 5](#SD6){ref-type="supplementary-material"} summarizes findings of studies incorporating quantitative imaging and genomics data in multiparametric models. Seven studies created prognostic models using whole-genome data and imaging \[[@R58]--[@R65]\]. Four studies successfully correlated quantitative perfusion traits with angiogenic gene signatures \[[@R66]--[@R69]\].

Non-small cell lung carcinoma: *EGFR*-mutations, *ALK*-rearrangements, *KRAS*-mutations {#s2_4}
---------------------------------------------------------------------------------------

Radiogenomic studies for NSCLC follow the emerging field of personalized, genotype-directed therapy for NSCLC ([Supplementary Table 8](#SD9){ref-type="supplementary-material"}). However, divergent findings were reported on the association between presence of *EGFR*-mutation (treatable with tyrosine kinase inhibitors, TKI) and imaging (standardized uptake value \[SUV\] on FDG-PET and proportion ground glass opacity \[GGO\] on CT). FDG-PET uptake was both negatively \[[@R70]--[@R77]\] and positively \[[@R78], [@R79]\] correlated with EGFR-mutations, while other studies found no correlation \[[@R74], [@R80]--[@R83]\]. Additionally, *EGFR*-mutated tumors were on average more solid (less GGO) \[[@R80], [@R84], [@R85]\], although not completely solid (some degree of GGO) \[[@R86]--[@R88]\]. However, one study showed an inverse relation \[[@R83]\] and other studies found no association \[[@R70], [@R78], [@R89]--[@R95]\]. Similarly, *ALK*-rearranged tumors (treatable with *ALK*-inhibitors) were more solid in two \[[@R95], [@R96]\] out of four \[[@R80], [@R85], [@R95], [@R96]\] studies compared with ALK-wild-type (wt) tumors. When using GGO to discriminate *ALK*-rearrangements from *EGFR*-mutations, *ALK*-rearranged tumors were more solid \[[@R80], [@R95]\]. Compared with *ALK*-wt, *ALK*-rearranged tumors had more spiculated \[[@R80]\] and lobulated \[[@R95]\] tumor margins on CT \[[@R80], [@R95]\]. Another driver mutation is *KRAS,* which is the most frequent driver mutation, but no CT or PET features were repeatedly associated with *KRAS*-mutation status ([Supplementary Table 9](#SD10){ref-type="supplementary-material"}).

Quantitative imaging and multiparametric modeling for radiogenomics in lung cancer {#s2_5}
----------------------------------------------------------------------------------

Recent studies performed multiparametric modelling and quantitative imaging in NSCLC \[[@R97]--[@R104]\]. Individual quantitative texture features successfully identified *EGFR*-mutation (multiple comparisons) \[[@R103], [@R104]\], as did multiparametric models adopting quantitative (AUC = 0.74--0.91), qualitative, (AUC = 0.89) \[[@R87]\], or combined quantitative-clinical features (AUC = 0.70) \[[@R98]\]. Quantitative CT- and PET-features could also predict *ALK* or *ROS1/RET* fusions (sens = 0.73, spec = 0.70) \[[@R105]\]. For development of prognostic imaging biomarkers, two groups used quantitative imaging for predicting prognosis-related gene clusters and found a lower kurtosis value linked with poorer survival \[[@R99]\]. Additionally, a module of tumor size, edge shape, and sharpness could predict survival \[[@R97]\]. Similarly, the prognostic value of PET-imaging was explained from a genomic perspective using radiogenomic analysis \[[@R100], [@R101]\].

Breast cancer {#s2_6}
-------------

This review only included studies with analyses on a genomic level; imaging-receptor associations based on immunohistochemistry analysis were reviewed elsewhere \[[@R10]\]. High FDG-PET uptake was found for gene expression signatures for basal like, while low uptake was found for luminal like cases \[[@R106]\]. Low FDG-PET uptake was also associated with expression of oestrogen-receptor related genes \[[@R107]\]. Other studies associated luminal B genes with quantitative dynamic MRI-perfusion \[[@R108]\] and *BRCA*-mutations with sharp margins and rim enhancement on MRI \[[@R109]\], but these findings were not independently validated.

Multiparametric modeling for radiogenomics in breast cancer {#s2_7}
-----------------------------------------------------------

Radiogenomic imaging models were used in breast cancer in twelve studies \[[@R110]--[@R121]\]. Five studies \[[@R110], [@R112], [@R118], [@R120], [@R121]\] focussed on Oncotype Dx gene-expression score, which predicts recurrence in early-stage ER+/HER2- invasive cancers \[[@R122]\]. One \[[@R118]\] additionally assessed prognostic gene assays MammaPrint \[[@R123]\] and PAM50 \[[@R124], [@R125]\]. Enhancement heterogeneity, on either quantitative perfusion \[[@R110], [@R120]\] or quantitative texture analysis \[[@R118]\], was associated with high-risk assays in three studies. Rapid contrast uptake predicted high-risk Oncotype Dx in two studies \[[@R110], [@R112]\]. To increase insight into underlying genomics of MR-perfusion parameters a study associated gene expression profiles with a heterogeneous centripetal perfusion phenotype \[[@R116]\] and another study associated perfusion parameters with regulatory non-coding transcripts of RNA associated with early metastasis \[[@R126]\]. Radiogenomics was applied for monitoring of anti-VEGF treatment by measuring pre- and post-treatment perfusion and associated differential gene expression \[[@R119]\]. Additionally, a qualitative imaging model including tumor heterogeneity and enhancement predicted expression of immune-response genes \[[@R114]\]. Combined analysis of tumor shape (lobulated oval) on mammography and MRI showed significant correlations with Oncotype Dx \[[@R121]\].

Colorectal cancer {#s2_8}
-----------------

Nine studies were included for CRC \[[@R127]--[@R135]\]. Higher FDG-PET uptake was found for *KRAS*-mutated tumors in five \[[@R128], [@R129], [@R133], [@R136], [@R137]\] out of six \[[@R134]\] studies. Additionally, *KRAS*-mutations could be predicted in a multiparametric model using high FDG-PET uptake in addition to CT texture and perfusion features \[[@R137]\]. Cases that were both *KRAS*- and *TP53*-mutated also showed a higher SUVmax \[[@R129]\], as did cases that belonged to the group "*KRAS*- or *BRAF*--mutated" \[[@R132]\].

Renal cell carcinoma {#s2_9}
--------------------

Eight studies were included for RCC \[[@R138]--[@R145]\]. *BAP1*-mutations, associated with invasive disease \[[@R146], [@R147]\], showed more calcifications (CT) in two studies, although in one non-significantly (*p* = 0.09 \[[@R138]\]; *p \<* 0.001 \[[@R140]\]). A radiogenomic risk score, based on a multiparametric qualitative CT model successfully predicted a predefined prognostic gene signature in RCC \[[@R142], [@R143]\]. One study identified genetic underpinnings of an imaging-based complication prediction score (PADUA) \[[@R145]\].

Hepatocellular carcinoma {#s2_10}
------------------------

Three studies were included for HCC \[[@R148]--[@R150]\]. Tumors with ill-defined margins on CT showed high expression of a gene expression signature for doxorubicin-sensitivity \[[@R150]\]. Additionally, targetable high *VEGF*-expression \[[@R151]\] was related to attenuation, heterogeneity and tumor margins on CT \[[@R148]\]. A gene signature of microvenous invasion (indicating poor prognosis) can be predicted by a CT biomarker including presence of small intratumoral internal arteries and the absence of hypodense halos \[[@R148]\]. A different genomic score for venous invasion was correlated with CT intratumoral arteries and margins \[[@R150]\].

Radiogenomics in other malignancies {#s2_11}
-----------------------------------

In paraganglioma, four studies found higher PET SUV-values for *SDHx*-mutated tumors \[[@R152]--[@R154]\] or *SHDx* and *VHL*-mutated tumors \[[@R155]\], relevant for heritability risk assessment. In head neck tumors, *EGFR*-expression was related to CT invasion, mass effect, size/volume \[[@R156]\] and lower capillary permeability on perfusion CT \[[@R157]\]. Additionally, 14 studies each reported on radiogenomic associations of 14 other malignancies, respectively (Table [3](#T3){ref-type="table"}).

###### Radiogenomics in other malignancies

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Diagnosis                                                               Study                                                                  Year                *N*   Study design (radiogenomic analysis)                                                                                                          Genetic feature                                                                          Significantly correlated imaging feature                                            *p*-value
  ----------------------------------------------------------------------- ---------------------------------------------------------------------- ------------------- ----- --------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------
  Cervical cancer                                                         Halle \[[@R194]\]                                                      2012                187   Prediction of expression of a set of hypoxia-induced genes with a DCE-MRI imaging model                                                       Hypoxia-induced genes set (31)                                                           DCE-MRI imaging feature model (Abrix)                                               Multiple significant finding, appendix S2

  Diffuse large B-cell lymphoma                                           Lanic \[[@R232]\]                                                      2011                57    Multiparametric modelling incorporating imaging (PET) and genomics to predict prognosis                                                       Germinal center B cell-like (GCB) vs Activated B cell-Like (ABC) (gene set expression)   PET High SUV-uptake                                                                 0.0291

  Extraskeletal myxoid chondrosarcoma                                     Tateishi \[[@R233]\]                                                   2005                19    Describing MR findings in 19 extraskelatal myxoid chondrosarcoma patients                                                                     EWS-CHN translocation vs other cytogenic variants                                        MR Peripheral enhancement                                                           \<0.05

  Lipoma and atypical lipomatous tumor/ well-differentiated liposarcoma   Brisson \[[@R234]\]                                                    2012                87    Identification of CT imaging biomarkers for *MDM2* amplifications (classified as atypical lipomatous tumor/well-differentiated liposarcoma)   *MDM2* amplification                                                                     CT Lesion size \>10 cm                                                              0.011

  CT Location: lower limb\                                                0.007                                                                                                                                                                                                                                                                                                                                                                                                                       
  CT Solid fat content                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                                                          0.002                                                                                                                                                                                                                                                                                                                                                                                                                       

  Melanoma brain metastases                                               Bordia \[[@R235]\]                                                     2016                98    Identification of MR imaging features of melanoma brain metastasis associated with genetic profiles and survival                              *BRAF* mutation                                                                          MR Size of lesions                                                                  \<0.05

  MR Edema MR Hyperintensity T1\                                          \<0.05                                                                                                                                                                                                                                                                                                                                                                                                                      
  MR Hyperintensity T2 compared to grey matter\                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  MR Enhancement\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  MR Diffusion characteristics                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  \<0.05                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  \<0.05                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  \<0.05                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  \<0.05                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Multiple myeloma                                                        Mai \[[@R236]\]                                                        2016                164   Identification of genetic underpinnings of qualitative MR imaging patterns                                                                    Any adverse cytogenetics (chrom. 17p deletion/t(4;14)/chrom. 1q21 gain)                  MR Diffuse patterns                                                                 0.02

  0.04                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Ovarian cancer (high grade serous)                                      Vargas \[[@R237]\]                                                     2015                46    Qualitative and quantitative assessment of CT features to predict gene expression subtypes (Clovar)                                           Mesenchymal gene expression subtype (Clovar)                                             CT Mesenteric infiltration                                                          0.002--0.005

  CT Diffuse peritoneal involvement                                       0.004--0.012                                                                                                                                                                                                                                                                                                                                                                                                                

  Neuroblastoma                                                           Liu \[[@R238]\]                                                        2015                42    Use of FDG-PET and FDOPA-PET for distinguishing neuroblastoma genomic subtypes                                                                *DDC* expression                                                                         PET FDG ratio to FDOPA negative                                                     0.02

  *HK2* expvression                                                       PET FDG ratio to FDOPA positive                                        \<0.0001                                                                                                                                                                                                                                                                                                                                             

  *Mycn* amplification                                                    PET FDG ratio to FDOPA positive                                        0.002                                                                                                                                                                                                                                                                                                                                                

  *SLC6A2* expression                                                     PET FDOPA uptake                                                       0.004                                                                                                                                                                                                                                                                                                                                                

  Medulloblastoma                                                         Perreault \[[@R239]\]                                                  2014                47    Qualitative assessment of MR imaging features to predict 4 molecular subgroups (wingless, sonic hedgehog, group 3, and group 4)               Group 3/4                                                                                MR Tumor location within the midline fourth ventricle                               \<0.001

  Wingless                                                                MR Tumor location cerebellar peduncle/cerebellopontine angle cistern   \<0.001                                                                                                                                                                                                                                                                                                                                              

  Sonic hedgehog                                                          MR Tumor location cerebellar hemispheres                               \<0.001                                                                                                                                                                                                                                                                                                                                              

  Group 4                                                                 MR No/minimal contrast enhancement                                     \<0.001                                                                                                                                                                                                                                                                                                                                              

  Group 3                                                                 MR Ill-defined tumor margins                                           0.03                                                                                                                                                                                                                                                                                                                                                 

  Pilocytic astrocytoma                                                   Zakrzewski                                                             2015                86    Identification of transcriptional profiles related to radiological findings                                                                   Transcriptional profiles                                                                 MR: Solid or mainly solid, Cystic/Enhanced, Cystic/Non enhanced, Largely necrotic   No relation found

  Pancreatic cancer                                                       Shi \[[@R131]\]                                                        2015                60    Correlation of PET-imaging features with major oncogenomic alterations                                                                        *CDKN2A* loss of heterozygosity                                                          PET (MTV and TLG)                                                                   0.029 0.021 resp.

  *SMAD4* loss of heterozygosity                                          PET (MTV and TLG)                                                      0.001 0.001 resp.                                                                                                                                                                                                                                                                                                                                    

  *TP53* mutation                                                         PET (MTV and TLG)                                                      0.001 0.001 resp.                                                                                                                                                                                                                                                                                                                                    

  Prostate cancer                                                         Stoyanova \[[@R240]\]                                                  2016                6     Multiparametric quantitative imaging association with whole genome(gene ontology) and predefined genomic classifiers                          Whole genome expression, predefined genomic classifiers                                  Multiple quantitative imaging features including DCE-MRI                            Significant findings for both predefined gene classifiers as newly identified pathways

  Thyroid cancer                                                          Nagarajah \[[@R241]\]                                                  2015                81    Identification of PET-imaging features related to BRAFv600E mutation                                                                          BRAFv600E mutation                                                                       PET SUVmax                                                                          0.019
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Oncology-wide comparison of radiogenomic correlations and gene pathway analysis {#s2_12}
-------------------------------------------------------------------------------

Looking at the molecular pathway-level, gene ontology analysis reveals associations between imaging groups and gene pathways in cancer (KEGG) oncology-wide (Table [4](#T4){ref-type="table"}). Distinct cancer pathways were associated with imaging group of necrosis (55 genes/6 pathways) and of contrast enhancement (37 genes/6 pathways). Enhancement features (degree) were associated with the targetable signalling pathways of VEGF (*p* \< 0.0001) and PI3K-Akt (*p* \< 0.0001) (Figure [3](#F3){ref-type="fig"}). In addition, enhancement was associated with mTOR signalling (*p* \< 0.0001), MAPK (*p* = 0.0004) signalling, Focal adhesion (*p \<* 0.0001) and Apoptosis (*p* = 0.0069). Necrosis was associated with PI3K-Akt signalling (*p* = 0.0005) (Figure [3](#F3){ref-type="fig"}), MAPK signalling (*p* = 0.0233), Wnt signalling (*p* = 0.0054), and p53 signalling (*p* = 0.0348). Furthermore, necrosis was significantly associated with Cell cycle (*p \<* 0.0001) and Focal adhesion (*p* = 0.0470).

###### Results of oncology-wide pathway analysis of radiogenomic associations: annotation for KEGG pathways in cancer

  Imaging group                 Genes in input (*n*)^b^   Genes from input available in pathway (*n*)   Genes in pathway annotation (*n*)   KEGG cancer pathway           *p*-value   *p* Bonferroni corrected
  ----------------------------- ------------------------- --------------------------------------------- ----------------------------------- ----------------------------- ----------- --------------------------
  necrosis degree               55                        9                                             124                                 Cell cycle                    \<0.0001    \<0.0001
  necrosis degree               55                        10                                            346                                 PI3K-Akt signalling pathway   0.0000      0.0005
  necrosis degree               55                        6                                             139                                 Wnt signalling pathway        0.0000      0.0054
  necrosis degree               55                        7                                             259                                 MAPK signalling pathway       0.0002      0.0233
  necrosis degree               55                        4                                             68                                  p53 signalling pathway        0.0003      0.0348
  necrosis degree               55                        6                                             206                                 Focal adhesion                0.0004      0.0470
  enhancement degree***^a^***   37                        12                                            346                                 PI3K-Akt signalling pathway   \<0.0001    \<0.0001
  enhancement degree            37                        8                                             206                                 Focal adhesion                \<0.0001    \<0.0001
  enhancement degree            37                        5                                             60                                  mTOR signalling pathway       \<0.0001    \<0.0001
  enhancement degree            37                        5                                             61                                  VEGF signalling pathway       \<0.0001    \<0.0001
  enhancement degree            37                        7                                             259                                 MAPK signalling pathway       0.0000      0.0004
  enhancement degree            37                        4                                             86                                  Apoptosis                     0.0001      0.0069

^a^We excluded enhancement pattern features. ^b^We required a minimal of 20 genes of radiogenomic associations for an imaging feature group (genes from input) for inclusion in analysis.

![Genetic traits associated with either enhancement or necrosis\
Genes associated with degree of enhancement (*N* = 37) and genes associated with necrosis (*N* = 55) are depicted. The genes *IDH1*, *NF1*, *TP53*, *PGF* and *EGFR* are shared between both groups. The two gene sets were both enriched for PI3K-Akt signalling (enhancement: 12 common genes, Bonferroni corrected *p* \< 0.0001; necrosis: 10 common genes, Bonferroni corrected *p* = 0.0005).](oncotarget-09-20134-g003){#F3}

[Supplementary Table 10](#SD11){ref-type="supplementary-material"} summarizes associations of imaging and individual genomic features that were found in multiple cancer types. Imaging groups (*N* = 14) comprised features (e.g. tumor size, multifocality) of both MRI and CT in various malignancies. Results included the correlations of enhancement features with *VEGF*-expression in brain tumors (glioblastoma) \[[@R158]\] and head-neck tumors (oral cavity SCC) \[[@R156]\].

DISCUSSION {#s3}
==========

This study provided a comprehensive database of imaging-genomics associations, in which queries can be made ([Supplementary Table 2](#SD3){ref-type="supplementary-material"}). This review focussed on both imaging-genomics associations with possible clinical application per cancer subtype and oncology-wide patterns in radiophenotype-genotype relations.

Diffuse glioma {#s3_1}
--------------

The 2016 WHO classification for diffuse glioma in adults is largely based on *IDH1*-mutation status and 1p/19q codeletion \[[@R159]\]. However, biopsy-based genotyping is an invasive technique that can be unreliable due to spatial tumor heterogeneity. Imaging biomarkers reflect the whole tumor and could possibly enhance genotyping accuracy non-invasively. Compared to *IDH*-wild type, *IDH*-1/2 mutated glioma have a favourable prognosis \[[@R21]--[@R23], [@R160]\]. *IDH*-status is the top-level diagnostic stratification after histology in the WHO index 2016 \[[@R159]\]. Although 12 out of 15 studies identified associations between imaging and *IDH*-status, the majority of findings were not independently validated. MR-perfusion \[[@R27], [@R28]\] and 2-HG MR-spectroscopy parameters \[[@R30], [@R31], [@R161]\], however, were correlated with *IDH*-status in multiple studies and yield potential for future imaging-based *IDH*-mutation detection. The oncometabolite 2-HG is elevated in *IDH*-mutated cases and can be depicted using MR-spectroscopy \[[@R29], [@R162]--[@R164]\], although this is technically challenging due to overlap of neighbouring metabolites (GABA, glutamate and glutamine) in the spectrum. State-of-the-art MR systems generate the high-quality spectra needed for 2-HG detection, enabling clinical practice integration \[[@R165]\]. The codeletion of chromosome 1p19q is an early genetic event in development of oligodendroglioma associated with greater chemosensitivity and improved survival \[[@R24]--[@R26], [@R159]\]. 1p19q co-deleted tumors were repeatedly characterised as heterogeneous \[[@R36]--[@R39]\] with ill-defined margins \[[@R36]--[@R39]\]. This phenotype is possibly caused by enhanced invasiveness of 1p19q co-deleted glioma. *MGMT*-methylated glioblastoma respond better to DNA alkylating chemotherapy with improved prognosis \[[@R41], [@R42]\]. The finding that *MGMT*-methylated cases showed higher ADC-values on DWI-MRI \[[@R27], [@R44]--[@R47]\] may only be relevant for detecting non-methylated, bad-responding elderly patients who may decide to refrain from treatment \[[@R166], [@R167]\]. *EGFR* aberrations were often correlated with MR-perfusion parameters, possibly due to the effect of *EGFR* on cell invasiveness and angiogenesis. However, despite the important role of *EGFR* in glioma development \[[@R168]\], suitable *EGFR*- targeted therapies for glioma have not been developed \[[@R169]\]. To ensure standardised glioma imaging features, models increasingly adopt quantitative imaging. Models allow for incorporating multidimensional parameters. Machine learning techniques are successfully adopted to optimize feature selection \[[@R34], [@R170], [@R171]\]. Potentially applicable models were found using quantitative features (3D texture, shape) \[[@R62]\], and a combination of quantitative and qualitative features (volume, haemorrhage, T1/FLAIR ratio) \[[@R59]\], both stratifying for survival and unique pathway activity. Additionally, prognostic models using quantitative imaging recently entered the phase of being tested in prospective setting \[[@R69], [@R171]\]. Although quantitative radiogenomic analyses showed great potential for genotyping in glioma, the vast variety of features and study designs made comparing results challenging.

Non-small cell lung cancer {#s3_2}
--------------------------

Since specific therapies are available for genomic subgroups of NSCLC, genotyping is important for directing therapy \[[@R172]\]. However, biopsy-based genotyping can cause treatment delay \[[@R173]\]. Radiogenomics may provide a reliable non-invasive tool for fast genotyping. *EGFR*-mutated \[[@R174], [@R175]\] and *ALK*-rearranged \[[@R172], [@R176], [@R177]\] tumors are targetable and are therefore extensively researched in radiogenomics. Repeatedly, FDG-PET was associated with *EGFR*-mutations, which may be biologically explained by the activating role of mutated *EGFR* glycolysis through AKT-signalling \[[@R178], [@R179]\]. The major studies showed a higher FDG-PET uptake for *EGFR*-mutated tumors; one of these validated their results in an independent cohort \[[@R73]\]. The three studies that found a lower uptake for *EGFR*-mutated cases were possibly unreliable because lower uptake was either not confirmed in multivariate analysis \[[@R76]\], found in metastasis only \[[@R75]\], or found because the comparison group had highly avid *KRAS*-cases \[[@R77]\]. Proportion GGO versus solid appearance on CT might be useful to differentiate genetic NSCLC-subtypes. Seemingly, wild type tumors have a large proportion GGO, *EGFR*-mutated tumors have a small component GGO, and *ALK*-rearranged tumors are the most solid. However, validation studies with standardised GGO measurements are needed to reliably discriminate genotypes. Similarly, standardised tumor morphology features need to be assessed in order to validate the predictive value of ill-defined tumor borders for *ALK*-status. Multiparametric (quantitative imaging) studies can be powerful for predicting individual genetic traits, as well as gene clusters related to prognosis. However, findings need to be validated in independent cohorts before they can be used in clinical practice.

Breast cancer {#s3_3}
-------------

In breast cancer, most radiogenomic associations were not independently validated. Limited results indicate FDG-PET can possibly discriminate molecular subtypes \[[@R106], [@R107]\]. Gene-expression scores such as Oncotype Dx recurrence risk test and MammaPrint metastasis risk test become increasingly important for clinical decision making in breast cancer, especially to prevent unnecessary chemotherapy. Since genetic tests are costly and time-consuming, studies aimed at finding imaging surrogates. In multiple studies perfusion features showed potential for predicting high-risk genetic tests, indicating tumor perfusion may be sign of poor prognosis in breast cancer. Studies furthermore indicated the potential of perfusion imaging for predicting gene expression markers for anti-VEGF treatment response. However, clinically applicable models are yet to be established.

Colorectal carcinoma, renal cell carcinoma, hepatocellular carcinoma {#s3_4}
--------------------------------------------------------------------

In colorectal carcinoma, *KRAS*-mutation indicates irresponsiveness to *EGFR*-targeted treatment \[[@R180], [@R181]\] and showed high FDG-PET uptake in multiple studies. The lack of this association in one study \[[@R134]\] and a reported low accuracy for prediction \[[@R129]\] might be explained by false-positive high uptake due to inflammation \[[@R136]\]. Although findings are not yet prospectively validated, FDG-PET has great potential for providing biomarkers for *EGFR*-treatment decision making in CRC. In renal cell carcinoma, the amount of calcifications shows potential for predicting *BAP1*-status, which could be useful for assessing stage, grade and invasiveness \[[@R146], [@R147]\]. However, findings need validation. Although multiparametric modelling studies in RCC were limited, great strides are put in assessing its application for predicting prognosis- and complication risk \[[@R142], [@R143], [@R145]\]. For hepatocellular carcinoma, radiogenomic biomarkers could aid both treatment selection (*VEGF*-targeted and doxorubicin treatment) as well as prognosis prediction. Microscopic venous invasion, a sign of poor prognosis and high recurrence risk, was associated with small intratumoral arteries (CT), which was independently validated \[[@R182]\]. However, it was noticed patients were not selected indiscriminately \[[@R183]\]. The amount of studies and their population size were too low to draw conclusions.

Patterns in radiogenomic associations {#s3_5}
-------------------------------------

Repeatedly found imaging-genomics associations show patterns among different neoplasms. A convincing relation was found for enhancement on imaging and *VEGF*-expression, identified in brain and head neck cancers. The same association was found in a study (not included) assessing radiogenetics using immunohistochemistry in HCC \[[@R184]\]. For a more profound understanding of radiogenomic relations and underlying regulatory networks, insights into the related biological process can be of considerable value. Angiogenesis was the most mentioned biologic link between imaging and genomics in glioblastoma \[[@R48], [@R54], [@R55], [@R57], [@R66], [@R67], [@R158]\], oligodendroglioma \[[@R56], [@R185]\], breast cancer \[[@R102], [@R126]\], oral cavity SCC \[[@R156]\], and RCC \[[@R138]\]. Angiogenesis-related genes such as *VEGF* and *EGFR* genes were compared with angiogenesis related imaging features such as perfusion and contrast enhancement. Similarly in gene pathway analysis, angiogenesis (biology) may be the link between enhancement (imaging) and VEGF-pathway-signalling (genomics).

Oncology-wide gene pathway analysis of radiogenomic associations {#s3_6}
----------------------------------------------------------------

The importance of targeting multiple regulators in cancer pathways instead of single genes, is increasingly recognized. Genes associated with enhancement were enriched for the VEGF-signalling pathway. Similar to the association between contrast enhancement and the *VEGF* gene, enhancement may be associated with the VEGF signalling pathway due to its regulating role in angiogenesis. Imaging biomarkers for the VEGF pathway may have clinical implications as they could aid patient selection for *VEGF*-targeted treatment. *VEGF*-targeted therapy has been shown to be effective in various cancer types, including CRC, NSCLC, and breast cancer \[[@R186], [@R187]\].

Gene pathway analysis results indicated furthermore that contrast enhancement and necrosis detected with imaging reflect MAPK- and PI3K-Akt-mTOR-activity. Similarly, this could again aid patient selection in the future for MAPK- and PI3K-AKT-mTOR pathways-based targeted therapies \[[@R188]--[@R190]\]. An important limitation for the gene pathway analysis was, nevertheless, the heterogeneity of the imaging features within the particular imaging feature groups. To minimize this effect, specific subgroups were created such as "enhancement patterns" and "amount of enhancement". Another important limitation for this analysis was that different types of genomics information (e.g. gene mutation vs gene expression) were described in literature. In addition to that, alterations can in principle result in either the activation or repression of the involved gene. In the performed analysis, the direction of the change, activation versus repression, could not be taken into account. Therefore, this analysis could only reveal associations.

Although evidently standardised imaging features and genetic tests are needed for further validation, results of this gene pathway analysis do reveal that oncology-wide associations between imaging groups and oncology pathways with potentially clinical value may exist. Our findings do not only indicate radiophenotype-genotype associations could be similar in different cancer types, but also imply that radiogenomics could aid patient selection and monitoring of pathway-targeted treatment in the future.

Radiogenomics techniques {#s3_7}
------------------------

Different approaches were seen for conducting radiogenomics analysis. A considerable disadvantage of qualitative imaging assessment is the poor interobserver agreement. A powerful tool to overcome this is a validated feature set, such as VASARI \[[@R191]\] for glioma imaging \[[@R58], [@R60], [@R64], [@R192]\]. The rapidly rising capacity of quantitatively computer-extracted imaging (perfusion-, diffusion- and texture features) enables more powerful and robust prediction of genomic traits. This radiogenomic approach has proven to be powerful for prognosis-prediction \[[@R58]--[@R64], [@R97], [@R99], [@R142]\], and for revealing differential pathway-activity \[[@R60], [@R148], [@R193], [@R194]\]. The trend in radiogenomics is increasingly headed towards models of multiparametric multilevel (clinical, radiological and histopathological) data, unravelling radiogenomic networks \[[@R58], [@R63], [@R64], [@R105], [@R116]\]. Methodologically, however, the use of quantitative imaging is still developing. Reproducibility of quantitative parameters is a major concern, since they are highly dependent on scanner systems and software packages. Particularly in MRI, it remains challenging, as it has less standardised quantitative values compared with CT- or PET-imaging. Moreover, overfitting of data models can be an issue. Standardised datasets such as The Cancer Imaging Archive (TCIA) \[[@R195]\] and The Cancer Genome Atlas (TGCA) \[[@R196]\] can provide a solution for validation in an independent cohort. Standardization of methods and prospective validation are needed before quantitative radiogenomics can be treatment informative.

Limitations {#s3_8}
-----------

A limitation of this study was the marked heterogeneity of genomic and imaging features and the variety of analysing methods which made data integration challenging. Another constraint was that the effect size and the direction of associations were not always reported. There might have been publication bias for significant findings, but the novelty of this field of research reduces this risk. A limitation was that data of included multiparametric modelling studies were usually not published online, so these *p*-values could not be incorporated in the database.

Potential of radiogenomics {#s3_9}
--------------------------

Radiogenomic genotyping has the advantage that it can capture tumor heterogeneity, can be performed repeatedly for treatment monitoring, and can be performed in malignancies for which biopsy is not available. Moreover, radiogenomics is cost-effective using routine clinical imaging for analysis. The gene pathway analysis in this study revealed imaging-genomic networks in oncology and indicated that radiogenomics may be suitable for predicting efficacy of pathway-targeted therapies. Although an extensive amount of potentially valuable radiogenomic biomarkers was identified, validation studies are needed since the robustness of features obtained by different scanners remains an important concern. This study provides an extensive database of imaging-genomic associations that can guide future research to developing radiogenomic tools for treatment selection and prognosis prediction in human oncology. Radiogenomics, connecting multiparametric quantitative imaging with genomic data, yields great potential for non-invasive genotyping, thereby contributing to the shift towards precision medicine in oncology.

METHODS {#s4}
=======

We performed this study according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@R197]\].

Search strategy and article selection {#s4_1}
-------------------------------------

We systematically searched the Medline and Embase databases for English literature published until 1-2-2017 on radiogenomics in oncology with search terms referring to radiogenomics and oncology ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). References of included articles and literature reviews were checked for additional eligible studies. The following inclusion criteria were adopted: (1) the population consisted of human cancer patients; (2) the article comprised statistically assessed associations between imaging features on CT, MRI, FDG-PET or mammography and genomics; and (3) full-text was available in English. We excluded studies performing radiogenetics using immunohistochemistry analysis. We excluded case reports, editorial letters, and reviews.

Extraction of study characteristics, quality checklist {#s4_2}
------------------------------------------------------

Study characteristics, quality assessment, *p*-values for associations and effect measures were incorporated in a database ([Supplementary Table 2](#SD3){ref-type="supplementary-material"}). *P*-values of studies using an extensive amount of quantitative imaging features or multiparametric models were reviewed separately. For quality assessment, the QUADAS-2 checklist \[[@R198]\] was used, with additional items to address radiogenomics specifically, including the availability of an independent validation cohort. All data generated or analysed during this study are included in this published article (and its Supplementary Information files).

Oncology-wide gene pathway analysis {#s4_3}
-----------------------------------

Gene pathway analysis was performed to examine concordance between grouped radiophenotypes oncology-wide and gene pathways. For this analysis, imaging features were classified for 14 coherent imaging groups. Significant radiogenomic associations for each imaging group were selected. Only single genes were selected (e.g. no chromosome-type aberrations), and the genes were annotated according to the HUGO Gene Nomenclature Committee (HGNC) nomenclature, regardless of neoplasm location or type of genetic information (DNA mutation, gene expression (mRNA), methylation status). A minimum of 20 genes per imaging feature group was required for inclusion in the analysis. Gene pathway analysis was performed by comparing significantly associated genes within a particular imaging group with already existing functional gene pathway annotations; the cancer gene pathways in the Kyoto Encyclopaedia of Genes and Genomes (KEGG) database \[[@R193], [@R199]\]. The ToppGene Suite software (Division of Biomedical Informatics, Cincinnati Children\'s Hospital Medical Center, Cincinatti, OH; <https://toppgene.cchmc.org/>)) was used for gene pathway analysis based on functional annotation, calculating *p*-values using the hypergeometric probability mass function. method. *P*-values were corrected for multiple testing using the Bonferroni method (cutoff value 0.05).

SUPPLEMENTARY MATERIALS TABLES {#s5}
==============================

**Note**

Callouts for the below references are included into [Supplementary Tables 4](#SD5){ref-type="supplementary-material"}, [5](#SD6){ref-type="supplementary-material"} and [8](#SD9){ref-type="supplementary-material"} respectively.

\[[@R207], [@R208]\], \[[@R209], [@R210], [@R211], [@R212], [@R213], [@R214], [@R215], [@R216], [@R217], [@R218], [@R219]\], \[[@R220], [@R221], [@R222], [@R223], [@R224], [@R225], [@R226], [@R227], [@R228], [@R229], [@R230], [@R231]\].
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